NVIV - InVivo Therapeutics Holdings Corp.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

7.14

-0.42 (-5.56%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	7.56
Open	7.60
Bid	6.50 x 1100
Ask	7.80 x 1100
Day's Range	7.03 - 7.60
52 Week Range	6.25 - 96.25
Volume	70,095
Avg. Volume	110,858

Market Cap	11.174M
Beta	1.93
PE Ratio (TTM)	N/A
EPS (TTM)	-0.81
Earnings Date	May 2, 2018 - May 7, 2018
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	118.75

Trade prices are not sourced from all markets

All

News

Press Releases

Associated Press15 days ago
InVivo: 1Q Earnings Snapshot
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $3.34. InVivo shares have decreased 57 percent since the beginning of the year. In the final minutes of trading on ...
Business Wire15 days ago
InVivo Therapeutics Reports 2018 First Quarter Financial Results
InVivo Therapeutics Holdings Corp. today provided a business and clinical update and reported financial results for the quarter ended March 31, 2018.
ACCESSWIRElast month
Today’s Research Reports on Stocks to Watch: vTv Therapeutics and InVivo Therapeutics
Shares of InVivo also headed higher after a reverse stock split this week. InVivo is also in the process of finalizing a lease assignment that the company expects will result in lease-related savings of approximately $3M through 2019.
Business Wirelast month
InVivo Therapeutics Provides Business Update
InVivo Therapeutics Holdings Corp. today provided a general business update. The company is announcing a 1-for-25 reverse stock split of its common stock and a proportionate reduction in its authorized common stock.
Business Wire2 months ago
InVivo Therapeutics Announces Contemporary Thoracic SCI Registry Study (the “CONTEMPO Registry Study”) Findings
InVivo Therapeutics Holdings Corp. today announced top-line findings from its CONTEMPO Registry Study, designed to provide comprehensive natural history benchmarks for Neuro-Spinal Scaffold™ clinical study results.
Associated Press2 months ago
InVivo reports 4Q loss
The Cambridge, Massachusetts-based company said it had a loss of 13 cents per share. For the year, the company reported that its loss widened to $26.7 million, or 81 cents per share. The company's shares ...
Business Wire2 months ago
InVivo Therapeutics Reports 2017 Year-end Financial Results
InVivo Therapeutics Holdings Corp. today reported financial results for the year ended December 31, 2017.
Simply Wall St.2 months ago
Is It Time To Buy InVivo Therapeutics Holdings Corp (NASDAQ:NVIV)?
InVivo Therapeutics Holdings Corp (NASDAQ:NVIV), a medical equipment company based in United States, led the NasdaqGM gainers with a relatively large price hike in the past couple of weeks. Less-covered,Read More...
ACCESSWIRE2 months ago
Today’s Research Reports on Stocks to Watch: Johnson & Johnson and InVivo Therapeutics
NEW YORK, NY / ACCESSWIRE / March 9, 2018 / Shares of Johnson & Johnson saw a slight close in the green yesterday despite announcing that the average price paid for its medicines had dropped last year. ...
Business Wire2 months ago
InVivo Therapeutics Receives FDA Approval for Pivotal, Randomized, Controlled Trial of the Neuro-Spinal Scaffold™ in Patients with Acute Spinal Cord Injury
InVivo Therapeutics Holdings Corp. today announced that the company has received supplemental Investigational Device Exemption approval from the US Food and Drug Administration for a second pivotal clinical study of the company’s Neuro-Spinal Scaffold™ in patients with acute spinal cord injury .
Business Wire3 months ago
InVivo Therapeutics Announces Appointment of Richard Toselli, M.D., as President and Chief Executive Officer
InVivo Therapeutics Holdings Corp. today announced that Richard Toselli, M.D., has been appointed President and Chief Executive Officer of InVivo, having been appointed the company’s Acting CEO in December 2017.
ACCESSWIRE4 months ago
Blog Exposure - InVivo Therapeutics Signs Share Repurchase Agreement with Lincoln Park Capital
LONDON, UK / ACCESSWIRE / January 29, 2018 / Active-Investors.com has just released a free research report on InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV ) ("InVivo Therapeutics"). If you ...
Business Wire4 months ago
InVivo Therapeutics Announces Purchase Agreement for up to $15 Million with Lincoln Park Capital
InVivo Therapeutics Holdings Corp. today announced that it has entered into a common stock purchase agreement with Lincoln Park Capital Fund, LLC , a
Business Wire5 months ago
InVivo Therapeutics Announces Latest Results from INSPIRE and Provides Update on Proposed Clinical Path Forward
InVivo Therapeutics Holdings Corp. today announced the latest results from The INSPIRE Study .
Business Wire5 months ago
InVivo Therapeutics Announces Executive Management and Board Changes
InVivo Therapeutics Holdings Corp. today announced that Richard Toselli, M.D., has been appointed Acting Chief Executive Officer of InVivo, replacing Mark D. Perrin, who has resigned as Chief Executive Officer and Chairman of InVivo’s Board of Directors.
Associated Press7 months ago
InVivo reports 3Q loss
The Cambridge, Massachusetts-based company said it had a loss of 28 cents per share. In the final minutes of trading on Monday, the company's shares hit $1.45. A year ago, they were trading at $4.40. _____ ...
Simply Wall St.7 months ago
What Is InVivo Therapeutics Holdings Corp’s (NVIV) Share Price Doing?
InVivo Therapeutics Holdings Corp (NASDAQ:NVIV), a healthcare equipment and supplies company based in United States, saw a significant share price rise of over 20% in the past couple of monthsRead More...
Business Wire7 months ago
InVivo Therapeutics Announces Oral Platform Presentation at 2017 Congress of Neurological Surgeons Annual Meeting
InVivo Therapeutics Holdings Corp. today announced that Stuart Lee, M.D., Investigator at Vidant Medical Center in Greenville, North Carolina, will be giving an oral platform presentation titled “Histopathology of Necrotic Spinal Cord Tissue Exudate Collected During Surgical Implantation of a Biodegradable Scaffold Following Acute Spinal Cord Injury: Pre-clinical and Clinical Findings” at the 2017 ...
Business Wire8 months ago
InVivo Therapeutics to Present at Ladenburg Thalmann 2017 Healthcare Conference
InVivo Therapeutics Holdings Corp. today announced that Mark Perrin, Chief Executive Officer and Chairman, will present at the Ladenburg Thalmann 2017 Healthcare Conference on Tuesday, September 26, 2017 at 12:00pm ET at the Sofitel New York Hotel, in Manhattan.
Business Wire9 months ago
InVivo Therapeutics Announces Publication in Neurosurgery of Lifetime Hospitalization Costs for Thoracic Spinal Cord Injury Patients by Severity Grade
InVivo Therapeutics Holdings Corp. today announced the publication of an article titled “Relationship of American Spinal Injury Association Impairment Scale Grade to Post-injury Hospitalization and Costs in Thoracic Spinal Cord Injury” in the journal Neurosurgery.
Business Wire9 months ago
InVivo Therapeutics Announces Strategic Corporate Restructuring
InVivo Therapeutics Holdings Corp. today announced that it is executing a strategic restructuring in order to focus on The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury.
Business Wire9 months ago
InVivo Therapeutics Announces Exchange of Certain Warrants for Common Stock
InVivo Therapeutics Holdings Corp. today announced that it had exchanged certain outstanding warrants that were issued as part of a financing in 2014 for shares of the company’s common stock.
Associated Press9 months ago
InVivo reports 2Q loss
The Cambridge, Massachusetts-based company said it had a loss of 20 cents per share. The company's shares closed at $1.80. A year ago, they were trading at $6.36. _____ This story was generated by Automated ...